The endoscopically placed duodenal–jejunal bypass liner (DJBL) or EndoBarrier gastrointestinal liner has been designed for the treatment of type 2 diabetes mellitus and simultaneous achievement of weight loss by obese patients. This study was performed to determine the safety, efficacy, and feasibility of delivering the DJBL with the patient under conscious sedation (CS). The primary end points of the study were safety and complications. The secondary end points were delivery time (min), amount of propofol (mg) used, and the total hospital stay (h).
This prospective study compared placement of the DJBL with the patient under propofol sedation and placement with the patient under general anesthesia (GA). The study included 56 patients, with 28 patients in each group.
Both groups were comparable in terms of age, gender, and body mass index. All the devices were placed successfully, and no complications occurred in either group. Comparison of the CS group with the GA group respectively showed a mean total operation time of 29 versus 56 min, a mean propofol use of 170 versus 258 mg, and a mean hospital stay of 11 versus 22 h.
Delivery of the DJBL to patients under CS is feasible, safe, and efficient in terms of time and cost. Because of possible complications during the procedure, the authors recommend placement of the DJBL with the patient under CS in proximity to the operating room.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303:235–241
Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053
Kelly T, Yang W, Chen CS, Reynolds K, He J (2008) Global burden of obesity in 2005 and projections to 2030. Int J Obes 32:1431–1437
Buchwald H, Avidor Y, Braunwald E, Jansen MD, Pories W, Fahrbach K (2004) Bariatric surgery: a systemic review and meta-analysis. JAMA 292:1724–1737
Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ (2009) The clinical effectiveness and cost effectiveness of bariatric (weight loss) surgery for obesity: systematic review and economic evaluation. Health Technol Assess 13(1–190):215–357
Heo YS, Park JM, Kim YJ, Kim SM, Park DJ, Lee SK, Han SM, Shim KW, Lee YJ, Lee JY, Kwon JW (2012) Bariatric surgery versus conventional therapy in obese Korea patients: a multicenter retrospective cohort study. J Korean Surg Soc 83:335–342
Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Ouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351:2683–2693
Buchwald H, Oien DM (2009) Metabolic/bariatric surgery worldwide 2008. Obes Surg 19:1605–1611
Morino M, Toppino M, Forestieri P, Angrisani L, Allaix ME, Scopinaro N (2007) Mortality after bariatric surgery: analysis of 13,871 morbidly obese patients from a national registry. Ann Surg 246:1002–1007 (Discussion 1007–1009)
Schauer P, Chand B, Brethauer S (2007) New applications for endoscopy: the emerging field of endoluminal and transgastric bariatric surgery. Surg Endosc 21:347–356
Hazey JW, Dunkin BJ, Melvin WS (2007) Changing attitudes toward endoluminal therapy. Surg Endosc 21:445–448
Malik A, Mellinger JD, Hazey JW, Dunkin BJ, MacFadyen BV Jr (2006) Endoluminal and transluminal surgery: current status and future possibilities. Surg Endosc 20:1179–1192
Gostout CJ, Rajan E (2005) Endoscopic treatments for obesity: past, present, and future. Gastroenterol Clin North Am 34:143–150
Cote GA, Edmundowicz SA (2009) Emerging technology: endoluminal treatment of obesity. Gastrointest Endosc 70:991–999
Schouten R, Rijs CS, Bouvy ND, Hameeteman W, Koek GH, Janssen IM, Greve JW (2010) A multicenter, randomized efficacy study of the EndoBarrier gastrointestinal liner for presurgical weight loss prior to bariatric surgery. Ann Surg 251:236–243
Rodriguez-Grunert L, Galvao Neto MP, Alamo M, Ramos AC, Baez PB, Tarnoff M (2008) First human experience with endoscopically delivered and retrieved duodenal–jejunal bypass sleeve. Surg Obes Relat Dis 4:55–59
Rodriguez L, Reyes E, Fagalde P, Oltra MS, Saba J, Aylwin CG, Prieto C, Ramos A, Galvao M, Gersin KS, Sorli C (2009) Pilot clinical study of an endoscopic, removable duodenal–jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther 11:725–732
Tarnoff M, Rodriguez L, Escalona A, Ramos A, Neto M, Alamo M, Reyes E, Pimentel F, Ibanez L (2009) Open label, prospective, randomized controlled trial of an endoscopic duodenal–jejunal bypass sleeve versus low-calorie diet for preoperative weight loss in bariatric surgery. Surg Endosc 23:650–656
Gersin KS, Rothstein RI, Rosenthal RJ, Stefanidis D, Deal SE, Kuwada TS, Laycock W, Adrales G, Vassiliou M, Szomstein S, Heller S, Joyce AM, Heiss F, Nepomnayshy D (2010) Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc 71:976–982
de Moura EG, Martins BC, Lopes GS, Orso IR, de Oliveira SL, Galvao Neto MP, Santo MA, Sakai P, Ramos AC, Garrido Júnior AB, Mancini MC, Halpern A, Cecconello I (2012) Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal–jejunal bypass liner. Diabetes Technol Ther 14:183–189
de Moura EG, Orso IR, Martins Bda C, Lopes GS, de Oliveira SL, Galvao-Neto Mdos P (2011) Improvement of insulin resistance and reduction of cardiovascular risk among obese patients with type 2 diabetes with the duodenojejunal bypass liner. Obes Surg 21:941–947
Escalona A, Pimentel F, Sharp A, Becerra P, Slako M, Turiel D, Muñoz R, Bambs C, Guzmán S, Ibáñez L, Gersin K (2012) Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal–jejunal bypass liner. Ann Surg 255:1080–1085
Montana R, Slako M, Escalona A (2012) Implantation of the duodenal–jejunal bypass sleeve under conscious sedation. SOARD 8:63–65
Neupanea N, Schmidtb MF, Gulatic N, Perwaizd M, Hammoudeha F, Kennedya E, Zahira M, Enriqueze D (2011) Pretracheal abscess following two weeks of endotracheal intubation. Yale J Biol Med 81:9–13
Björntorp P (1997) Obesity. Lancet 350:423–426
Ray C, Sue D, Bray G, Hansen JE, Wasserman K (1983) Effects of obesity on respiratory function. Am Rev Respir Dis 128:501–506
Jennum P, Sjol A (1992) Epidemiology of snoring and obstructive sleep apnoea in a Danish population age 30–60. J Sleep Res 1:240–244
Simonds SE, Cowley MA (2013) Hypertension in obesity: is leptin the culprit? Trends Neurosci 36(2):121–132
Mikhail N, Golub MS, Tuck ML (1999) Obesity and hypertension. Prog Cardiovasc Dis 42:39–58
Duflou J, Virmani R, Rabin I, Burke A, Farb A, Smialek J (1995) Sudden death as a result of heart disease in morbid obesity. Am Heart J 130:306–313
The authors would like to thank Ishaq Ghariq for drawing the illustration (Fig. 1).
Parviez Koehestanie, Ignace Janssen, and Peter Wahab have received consultant fees and support for travel as proctors from GI Dynamics. Bark Betzel, Kemal Dogan, Frits Berends, Edo Aarts, and Marcel Groenen have no conflicts of financial ties to disclose.
About this article
Cite this article
Koehestanie, P., Betzel, B., Dogan, K. et al. The feasibility of delivering a duodenal–jejunal bypass liner (endobarrier) endoscopically with patients under conscious sedation. Surg Endosc 28, 325–330 (2014). https://doi.org/10.1007/s00464-013-3143-9
- Duodenal–jejunal bypass liner
- Type 2 diabetes mellitus
- Conscious sedation